Tandlægeholdingselskabet Gina Caspersen ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  28.5% 19.9% 17.2% 13.4% 8.4%  
Credit score (0-100)  3 6 9 16 28  
Credit rating  B B BB BB BB  
Credit limit (kDKK)  -0.0 0.0 -0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -252 -144 -194 -163 -32.5  
EBITDA  -892 -696 -909 -800 -775  
EBIT  -892 -696 -909 -800 -775  
Pre-tax profit (PTP)  173.0 82.5 0.1 269.9 593.4  
Net earnings  134.8 64.1 0.1 210.0 463.2  
Pre-tax profit without non-rec. items  173 82.5 0.1 270 593  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  210 219 162 315 719  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  382 448 524 682 1,211  

Net Debt  -172 -216 -90.2 -72.4 -813  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -252 -144 -194 -163 -32.5  
Gross profit growth  -40.8% 42.8% -34.6% 16.0% 80.0%  
Employees  0 0 0 0 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  382 448 524 682 1,211  
Balance sheet change%  76.0% 17.2% 17.1% 30.1% 77.6%  
Added value  -891.7 -696.3 -908.9 -800.4 -775.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -3.0 -4.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  353.8% 483.2% 468.5% 491.1% 2,381.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  59.3% 21.7% 1.9% 46.5% 64.0%  
ROI %  101.9% 40.7% 4.8% 117.6% 117.2%  
ROE %  79.5% 29.9% 0.0% 88.0% 89.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  54.9% 48.9% 31.0% 46.2% 59.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  19.3% 31.0% 9.9% 9.0% 104.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.3 1.1 0.3 0.2 1.7  
Current Ratio  2.3 1.1 0.3 0.2 1.7  
Cash and cash equivalent  172.0 216.0 90.2 72.4 812.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  219.2 11.4 -245.7 -285.0 -482.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 -775  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 -775  
EBIT / employee  0 0 0 0 -775  
Net earnings / employee  0 0 0 0 463